secwatch / observer
8-K filed May 24, 2023, 7:59 PM ET ticker ABCL CIK 0001703057
other material confidence high sentiment positive materiality 0.75

AbCellera enters $701M co-investment with Canadian, BC governments for antibody drug development

AbCellera Biologics Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

AbCellera Biologics Inc. entered into Canada Contribution Agreement with Government of Canada valued at Up to $166.7 million (CA$225.0 million) including non-repayable, repayable, and conditionally repaya (effective 2023-05-24).

Action
entry
Counterparty
Government of Canada
Value
Up to $166.7 million (CA$225.0 million) including non-repayable, repayable, and conditionally repaya
Effective
2023-05-24
Exact text from the filing
Pursuant to the Canada Contribution Agreement, the Government of Canada has committed up to $166.7 million (CA$225.0 million), of which $41.6 million (CA$56.2 million) is not repayable, $58.4 million (CA$78.8 million) is repayable and $66.7 million (CA$90.0 million) is conditionally repayable.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

AbCellera Biologics Inc. entered into BC Contribution Agreement with Government of British Columbia valued at Up to $55.6 million (CA$75.0 million) including partial reimbursement and conditional portions. (effective 2023-05-24).

Action
entry
Counterparty
Government of British Columbia
Value
Up to $55.6 million (CA$75.0 million) including partial reimbursement and conditional portions.
Effective
2023-05-24
Exact text from the filing
Pursuant to the BC Contribution Agreement, the Government of British Columbia has committed up to $55.6 million (CA$75.0 million) which includes partial reimbursement of certain eligible expenditures up to $27.8 million (CA$37.5 million) towards eligible infrastructure investments paid over five years; and a $27.8 million (CA$37.5 million) conditional portion paid upon achievement of certain defined milestones, including upon the Company’s undertaking of certain clinical trial activities in British Columbia.
View on SEC.gov

301 material agreements filed in the last 30 days. Browse all material agreements →

AbCellera Biologics Inc. filing history →

Source: SEC EDGAR
accession 0001703057-23-000011
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.